anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Agents, kits, and methods that utilize oxygenation to prevent and/or treat intestinal inflammation and/or infections caused by anaerobic microorganisms are provided. In several embodiments, the formulations are provided as a capsule within a capsule in order to separate an oxygen prodrug from a catalyst until the formulation is at a target site within the intestine. In several embodiments, the catalyst is provided in an excess of the oxygen prodrug. In several embodiments, the prodrug is within an inner capsule or coating and a biological material comprising a catalyst (e.g., yeast, spirulina, chlorella, etc.) surrounds the encapsulated prodrug and the biological material is within a capsule or coating. The agents, kits, and methods can be utilized to prevent and/or treat anaerobic bacterial infections of the intestinal lumen by enteric aerobization therapy.
All patients will also be exposed to a placebo light (80 lux, 470 nm) during the treatment phase, 3 times per day (morning, afternoon and evening) for 60 minutes each via goggles providing light at the eyes level. Meanwhile, different assessments will be performed in order evaluating the potential effects of provided light in comparison to placebo light. Patients will be given behavioral assessments (Coma Recovery Scale-Revised, Nociception Coma Scale-Revised, brainstem reflexes,...), physiological (body core temperature, saliva, urine, heart rate, blood sample), neuroimaging and neurophysiological tools (PET, fMRI, TMS-EEG, resting-state and auditory paradigm EEG) before, during and after treatment.
The acupoints of sham TTN group are the same as those of TTN group. The use of sham TTN was the same as that of the TTN group. After 3 days retention of sham NNT, the patient was instructed to go to the hospital, where the doctor removed the sham TTN, and conducted the next treatment after local skin disinfection. A total of 5 treatments were given for a duration of 15 days.
OBJECTIVE: Gaucher disease (GD) is a clinically rare single-gene recessive lysosomal storage disease mainly divided into three subtypes I to III. This report aims to present a case of type IIIb GD in a Chinese child with a focus on the manifestation of hearing loss and the importance of early diagnosis and monitoring.
METHODS: The patient underwent a routine physical examination upon admission, followed by CT scans of the chest and abdomen, MRI of the brain, and bone marrow smear examination. The patient's GBA enzyme activity, Lyso-GL-1 levels, and GBA gene expression were analyzed using tandem mass spectrometry (MS/MS) and next-generation sequencing technology. Finally, auditory brainstem response (ABR) testing was conducted.
RESULTS: This report presented a case of a Chinese boy with hematological manifestations as the first symptom, followed by hepatosplenomegaly, and the bilateral femurs showed obvious Erlenmeyer flask-like changes. Combined with GBA enzyme activity, Lyso-GL-1 and GBA genotype analysis results, the boy was initially diagnosed as type I GD. During the follow-up, the boy developed nystagmus, bilateral ABR V wave threshold increased, V/I amplitude ratio <0.5, accompanied by delayed growth and development, and finally diagnosed as type IIIb.
CONCLUSIONS: This case suggests the necessity of neuropathy monitoring in patients with type I GD during the early stages of the disease. This includes EEG, neuro-ophthalmological examination, and auditory function assessment, which can help reflect the progression of neuropathy and facilitate the early diagnosis of type III GD.
PURPOSE:To produce the title powder as the material for a sintered body having high strength and toughness by introducing a Zr compd., an alkaline soln., a Ca salt soln., and a phosphoric acid soln. into a reaction vessel, and agitating the mixture. CONSTITUTION:A Ca salt soln., a phosphate soln., an alkaline soln., and a Zr salt or hydrated zirconia are introduced into the reaction vessel, mixed, and subjected to a reaction. Alternatively, a slurry obtained by dispersing hydroxyapatite powder in water, an alkaline soln., and a Zr compd. are introduced into the reaction vessel, and mixed. By this method, the hydroxyapatite powder contg. the uniformly dispersed pulverized Zr compd. can be efficiently produced.
Pulmonary fibrosis (PF) is a chronic, progressive and irreversible interstitial lung disease that seriously threatens human life and health. Our previous study demonstrated the unique superiority of traditional Chinese medicine cryptotanshinone (CTS) combined with sustained pulmonary drug delivery for treating PF. In this study, we aimed to enhance the selectivity, targeting efficiency and sustained-release capability based on this delivery system. To this end, we developed and evaluated CTS-loaded modified liposomes-chitosan (CS) microspheres SM(CT-lipo) and liposome-exosome hybrid bionic vesicles-CS microspheres SM(LE). The prepared nano-in-micro particles system integrates the advantages of the carriers and complements each other. SM(CT-lipo) and SM(LE) achieved lung myofibroblast-specific targeting through CREKA peptide binding specifically to fibronectin (FN) and the homing effect of exosomes on parent cells, respectively, facilitating efficient delivery of anti-fibrosis drugs to lung lesions. Furthermore, compared with daily administration of conventional microspheres SM(NC) and positive control drug pirfenidone (PFD), inhaled administration of SM(CT-lipo) and SM(LE) every two days still attained similar efficacy, exhibiting excellent sustained drug release ability. In summary, our findings suggest that the developed SM(CT-lipo) and SM(LE) delivery strategies could achieve more accurate, efficient and safe therapy, providing novel insights into the treatment of chronic PF.
Patients who are admitted with acutely decompensated heart failure and are receiving intravenous diuretics will be recruited to undergo testing. Testing with the Indicor device will occur every day during hospitalization, and twice a day for up to 30 days after discharge.
PROBLEM TO BE SOLVED: To provide a system by which interaction data can simply be retrieved by utilizing a conventional database. SOLUTION: The line numbers L1 and the column numbers C1 of 1 to 10 are displayed at the side of a chart and the top of the chart of the matrix MX of 10×10. At the side of the chart, medical drug name input boxes L2, the number of documents display boxes L3, and warning display boxes L4 are provided corresponding to the line numbers L1 by one to one. On the upper side of the matrix MX, a retrieval execution button B1, a clear button B2, a representative product check button B3, and a non-representative product check button B4 are arranged. When interaction due to the combination use of inputted drugs A and B, e.g. as the result of retrieving an attached document, the matrix MX displays the effect in the square frame of a matrix where A and B cross with each other.  In the case of contraindication of combination use, the square frame is displayed in red, and the number of attached documents of A having B written in the box of contraindication of combination use is displayed in brackets is displayed with characters expressing 'contraindication'. In the case of caution of combination use, the square frame is displayed in yellow, and the number of attached documents of A having B written in the box of caution of combination use is displayed in brackets is displayed with characters expressing 'caution'.
ABSTRACT OF THE DISCLOSURE      The invention concerns new types of gel compositions and their manufacture; the gels contain an aluminium-magnesium-hydroxy compound having the general formula AlxMgy(OH)35-zRz?nH2O   in which R denotes the radical of a monocarboxylic acid where 3 ? x ? 9 4 ? y ? 13 3 ? z ?  5, and 3x+2y = 35, as well as a polar additive and an organic, lipophilic liquid. The new gel compositions may be used in cosmetics as rheological additives and anti-settling agents.
The data transmission device (8) comprises a separate interchangeable interface transducer detachably connected to a device body of the sphygmomanometer and to a connection interface of the measuring device by an internal connection interface (9). The data and/or transmission format is adapted to the measuring device and another data and/or transmission format is adapted to the respective external data processing device and/or vice-versa. The connection interface of the measuring unit is resistor serial port ( RS-232-port) and exhibits a chip card-contacting unit (12). The interface transducer has a protocol converter at the internal connection interface intended data transmission protocol and at the external transmission interface intended data transmission protocol and/or in reverse synchronization and has a level transducer at the internal connection interface intended data signal level and at the external transmission interface (10) intended data signal level. The external transmission interface of the interface transducer is instructed as infrared interface, fax modem, chip card terminals, cable connection interface, Bluetooth (RTM) unit, universal serial bus (USB) interface, as firewire port and/or as wireless local area network (WLAN) interface. The data transmission device comprises a charging circuit for electrical charge of a rechargeable battery arranged in device body of the sphygmomanometer and forms a plug connection with device body of the sphygmomanometer. The data transmission device and the connection interface are bi-directional units. An independent claim is included for data transmission unit for blood pressure measuring apparatus.
This study compares the effectiveness of verbal modeling, symbolic modeling, and verbal suggestion in inducing nocebo hyperalgesia. It is the first study to examine the contribution of stress to observationally induced nocebo hyperalgesia. This study's experimental groups represented various sources of social information: a group of people participating in the study (verbal modeling), a single participant (symbolic modeling), and an experimenter (verbal suggestion). During the experiment, participants received electrocutaneous stimuli at the same intensity, some of which were applied with a nocebo (sham device). Participants in the verbal modeling group were acquainted with pain ratings that had allegedly been provided by other participants. The ratings suggested that other participants experienced more pain in the nocebo trials than in the control trials. In the symbolic modeling group, participants observed a videotaped model experiencing more pain in the nocebo than in the control trials. In the verbal suggestion group, participants received a verbal suggestion of hyperalgesia in the nocebo trials and no suggestion in the control trials. No manipulations were used in the control group. To investigate whether nocebo hyperalgesia is stable over time, an additional extinction phase was conducted. Nocebo hyperalgesia was induced by verbal modeling only and was partially mediated by expectancy. Stress was a significant moderator of the induced effect. Nocebo hyperalgesia was extinguished during the extinction phase. The obtained results provide potential implications for minimizing nocebo hyperalgesia in clinical practice by, for instance, controlling patients' expectancies and stress levels. PERSPECTIVE: The study shows the role of pain-related information derived from other people in shaping negative treatment experiences in the individual. Because information from others has a particular impact on individuals experiencing stress, both this information and the stress level of patients should be monitored in the treatment process.
The invention relates to a method for the preparation of protein hydrolysate and to its application for suppressing any reactions of hypersensitivity caused by foods in patients suffering from digestion allergy. The hydrolysate is produced by an enzyme produced from probiotic gastrointestinal bacteria and pepsin and/or tripsin. The invention also relates to a method for the prevention or treatment of allergies in children, in particular of allergies to cows' milk, by increasing the diet for the elimination of cows' milk by suitable probiotic bacteria produced from the gastrointestinal tract, in particular Lactobacilli. The invention also relates to special products for allergic children with impaired intestinal barrier function. By applying fragments of allergen modified from gastrointestinal bacteria, the immune response can be reversed from sensibility to system hyporesponse. The bacteria preferable for application are Lactobacillus GG (ATCC 53103). 12 claims, 4 figures
INTRODUCTION: The prevalence of chronic kidney disease (CKD) is gradually increasing in the elderly population. At the same time, frailty has become one of the research hotspots in the field of geriatrics. Bibliometric analyses help to understand the direction of a field. Therefore, this study aimed to analyze the status and emerging trends of frailty in CKD patients.
DATA AND METHODS: The Web of Science Core Collection (WoSCC) database was screened for relevant literature published between 1 January 2000 and 31 December 2021. Next, publications were analyzed for information including authors, journals, cited references, citing journals, institutions, countries and regions, high-frequency keywords and co-citations using VOSviewer, Microsoft Excel, and R software.
RESULTS: A total of 2223 articles were obtained, from which 613 relevant articles were selected based on title and abstract screening. There was an upward trend in the number of annual publications and Johansen KL was considered the most contributing author in the field. The Clinical Journal of the American Society of Nephrology was the most productive research journal. Johns Hopkins University is the most published organization. The United States is the global leader in the field and contributes the most to research. Research hotspots focus on epidemiological studies of frailty and frailty intervention.
CONCLUSIONS: This study presents a comprehensive bibliometric analysis of CKD and frailty research. Key findings highlight the current focus on early screening and assessment of frailty in CKD patients, as well as physical function interventions in frail patients.
Olmesartan medoxomil was not carcinogenic when administered by dietary administration to rats for up to 2 years. The highest dose tested (2000 mg/kg/day) was, on a mg/m2 basis, about 480 times the maximum recommended human dose (MRHD) of 40 mg/day. Two carcinogenicity studies conducted in mice, a 6-month gavage study in the p53 knockout mouse and a 6-month dietary administration study in the Hras2 transgenic mouse, at doses of up to 1000 mg/kg/day (about 120 times the MRHD), revealed no evidence of a carcinogenic effect of olmesartan medoxomil. 

Both olmesartan medoxomil and olmesartan tested negative in the in vitro Syrian hamster embryo cell transformation assay and showed no evidence of genetic toxicity in the Ames (bacterial mutagenicity) test. However, both were shown to induce chromosomal aberrations in cultured cells in vitro (Chinese hamster lung) and tested positive for thymidine kinase mutations in the in vitro mouse lymphoma assay. Olmesartan medoxomil tested negative in vivo for mutations in the MutaMouse intestine and kidney and for clastogenicity in mouse bone marrow (micronucleus test) at oral doses of up to 2000 mg/kg (olmesartan not tested).

Fertility of rats was unaffected by administration of olmesartan medoxomil at dose levels as high as 1000 mg/kg/day (240 times the MRHD) in a study in which dosing was begun 2 (female) or 9 (male) weeks prior to mating.
Provided herein are methods of making vaccines for cancer immunotherapy. When the exosome is placed at normal temperature for a certain time, the membrane structure collapses and cannot be fused with dendritic cells. Therefore, it is necessary to perform heat treatment under conditions that promote the conversion of proteins into peptides and maintain the structure of the exosome membrane, which are 56 ℃ or less and 30 minutes or less. At temperatures above this range, proteins are denatured and cannot retain antigenicity. Therefore, by heat-treating exosomes (exosomes) isolated from body fluids such as cancer cells and blood of a cancer patient at 56 ℃ or lower and 30 minutes or lower, inactivation of protease in exosomes is promoted, and protein-degrading enzymes and lipid-degrading enzymes are inactivated. Then, the exosome is introduced into or co-cultured with dendritic cells induced from blood or the like of a cancer patient or a healthy person.
BACKGROUND: Rabies infection can occur in humans when key elements of the rabies PEP regimens are omitted or incorrectly administered. The CDC Advisory Committee on Immunization Practices (ACIP) recommends that patients who are exposed to rabies virus should receive prompt and thorough wound cleansing followed by administration of human rabies IG and rabies vaccine. Previous research identified three opportunities to improve adherence to CDC guideline recommendations for rabies PEP: (1) infiltration of rabies IG into and around the wounds, if anatomically feasible, (2) administration of rabies IG at an anatomical site distant from rabies vaccine administration, and (3) avoiding administration of rabies IG into the buttock.

STUDY DESIGN: This quasi-experimental, quality improvement study evaluates adherence to 6 quality indicators, which are based on CDC guideline recommendations, for patient selection and delivery of rabies IG before and after implementation of the rabies PEP quality improvement bundle. The quality improvement bundle includes EHR enhancements, ED staff education, and patient education. Patients who receive at least one dose of rabies IG or rabies vaccine at a study site during the study period will be included in this study. The historical control group includes patients treated prior to bundle implementation. The post-implementation group includes patients treated within 12 months following bundle implementation. The primary outcome is full adherence to all 6 quality indicators for rabies IG selection and delivery.
AIM: Depression, a prevalent mental disorder, significantly impairs the quality of life and social functioning. Targeting neuroinflammation is a promising therapeutic approach, highlighting the need for natural neuroprotective agents. Gypenosides (Gyp) from Gynostemma pentaphyllum exhibit anxiolytic and antidepressant effects, yet the underlying mechanisms remain unclear. We investigated whether Gyp, isolated and purified by our laboratory, can exert neuroprotective effects by modulating neuroinflammation in the hippocampus and prefrontal cortex (PFC) of mice with LPS-induced anxiety and depression, thereby ameliorating behavioral phenotypes.
METHODS: LPS (1 mg/kg, i.p.) was used to induce anxiety and depression-like behaviors. Gyp was administered at 50, 100, or 200 mg/kg in pretreatment, with fluoxetine hydrochloride (Flu) as a positive control, for 10 consecutive days.
RESULTS: Gyp, especially at 100 mg/kg, significantly ameliorated LPS-induced anxiety and depression in mice, normalizing cytokine expression in the hippocampus and PFC, with IL-1β showing the most pronounced regulation (Hippocampus: RatioGyp-100/LPS = 30.73 %, PFC: RatioGyp-100/LPS = 55.89 %). Gyp also reversed LPS-induced neuronal loss and necrosis, reduced glial cell activation, and prevented the transition of microglia to the M1 phenotype. Mechanistically, Gyp suppressed the activation of the NLRP3 inflammasome in the PFC, and modulated hippocampal synaptic protein loss, thereby mediating neuroinflammation.
CONCLUSIONS: Gyp improved anxiety and depression in LPS-induced mice, which may be achieved by balancing systemic inflammatory levels, regulating glial cell activation and phenotypic polarization, regulating hippocampal synaptic plasticity, and suppressing the NLRP3/Caspase-1/ASC signaling pathway in the PFC.
The invention relates to benzo heterocyclic compounds as protein kinase inhibitors and a preparation method and use thereof. The invention relates to formula (I) and (II) compounds and pharmaceutically acceptable salts and prodrugs thereof, and R1, R2, R3, R4, R5, R6, X1, X2 and X3 are as defined in the specification. The compounds are the protein kinase inhibitors, particularly are protein kinase inhibitors Mek inhibitors, and can be used for the treatment of cancer and inflammation in mammals. The present invention also discloses a method for using the compounds for treatment of cancer, inflammation and other diseases in the mammals and a pharmaceutical composition comprising the compounds. The invention relates to a preparation method of the benzo heterocyclic compounds. The patent mainly relates to preparation of the officinal compounds such as benzoxazole and benzothiazole derivatives and the like.
Lymph node metastasis (LNM) is a common invasive feature of hepatocellular carcinoma (HCC) associated with poor clinical outcomes. Through microarray profiling and bioinformatic analyses, we identified the circ-0044539-miR-29a-3p-VEGFA axis as a potential key factor in the progression of HCC LNM. In HCC cells and nude mice, circ-0044539 downregulation or miR-29a-3p upregulation was associated with small tumor size, PI3K-AKT-mTOR pathway inactivation, and downregulation of the key LNM factors (HIF-1α and CXCR4). Furthermore, circ-0044539 was also responsible for exosomal miR-29a-3p secretion. Exosomal miR-29a-3p was then observed to migrate to the LNs and downregulate High-mobility group box transcription factor 1 (Hbp1) in Polymorphonuclear Myeloid-derived suppressor cells (PMN-MDSCs), inducing the formation of a microenvironment suitable for tumor colonization. Overall, circ-0044539 promotes HCC cell LNM abilities and induces an immune-suppressive environment in LNs through exosomes, highlighting its potential as a target for HCC LNM and HCC immunotherapy.
This clinical trial is an open-label, one-time injection study in which scAAV1.tMCK.NTF3 will be administered by intramuscular injections into the medial and lateral heads of gastrocnemius, tibialis anterior, and rectus femoris muscles in both legs in CMT1A subjects with PMP22 gene duplication. Three CMT1A patients, 18 to 35 years of age will be enrolled into one cohort in this trial. These adult subjects will be enrolled at an effective dose (8.87e11 vg/kg) based on a qPCR titer using linearized standards, equivalent to 4.00x1012 vg/kg based on a qPCR titer using supercoiled standards) distributed bilaterally between both limbs in Cohort 1. Post-gene transfer monitoring will include follow up visits on days 7, 14, 30, 60, 90, 120, and months 6, 9, 12, 15, 18 and 24 following gene transfer. Safety is the primary endpoint for this clinical gene transfer trial. Stopping criteria are based on development of unacceptable toxicity defined as the occurrence of any one Grade III or higher, unanticipated, treatment-related toxicity. The secondary endpoint is efficacy defined as halting of the decline in functional and sensory abilities measured by the CMT Pediatric Scale (CMTPedS) at 2 years post gene transfer. The CMTPedS is an 11-item scale comprised of the Functional Dexterity Test, Nine-Hole Peg Test (9HPT), hand grip, foot plantar flexion, foot dorsiflexion, pinprick sensation, vibration sensation, the Bruininks Oseretsky Test- Balance assessment, gait assessment, long jump, and six-minute walk test (6MWT). Exploratory outcome measures will include 10 meter run/walk timed test (10M), 100 meter timed test (100M), peroneal and ulnar CMAP amplitude and sensory and motor conduction velocities, a revised sensory testing to increase sensitivity for pinprick, touch-test and vibration assessments, visual analogue scales for pain and fatigue, Short Form Health Survey (SF-36) as Quality of Life measure, and circulating NT-3 levels.